Amryt Pharma Share Discussion Threads

[moneytree1] 23/3/2018 12:32

I bet you will pappy....

[papillon] 23/3/2018 12:26

Not posting any opinion, just saying I've just bought 3,892 shares @ 17.73p (a tad below mid-price so it will most likely show as a sell). Total cost including commision of £700. Bought because the share price is hovering just above support. Might have jumped in too early, but it's only money after all! :-).

Now back to sleep until the next RNS. Probably the 2017 results forecast for mid April. Doubt I'll even read this bb in the meantime.

[digadee] 22/3/2018 16:38

Agree jimbob, well said

[bazworth] 22/3/2018 12:19

Totally agree Jimbob, very happy to hold as I see a very promising story unfolding here!!

[greendragon777] 20/3/2018 18:48

I think the share price will continue to slide like it did before the trading update Paps. With 6 odd months to go to the interims now I think it's gonna go very quiet around here for a while, barring another licencing deal of some description.

In relation to Amicus and sharing the data etc, I still believe there is a mutual interest in getting AP101 approval. I can see some sort of a deal happening between them at some stage down the road all going well.

We just have to exercise some more patience I guess.....if it's positive news in October then it will be a good way to round off the year!

Happy snoozin' Paps! :-)

[papillon] 20/3/2018 17:41

Almost resting on support. I would suspect a drop below this years low, achieved at the end of February, would give a further bearish signal.

I've lost interest in AMYT, at least for the time being, so I probably wont post on here again until we get the next RNS. That RNS could be the Final Results for 2017, forecast for the middle of next month. Au revoir.

[papillon] 20/3/2018 12:59

2 x 125k trades gone through @ 17.70p & 17.73p. DEFINITELY A ROLLOVER based on the times. Rollover done @ the bid price. 125k sold @ 17.70p followed a fraction of a second later by the buy back done @ 17.73p. Must have had an open position that needed to be closed. Let's hope he knows what he's doing.

125k @ 17.70p @ 11:35:18

125k @ 17.73p @ 11:35:28

[papillon] 20/3/2018 11:20

moneytree1 20 Mar '18 - 11:18 - 2543 of 2543 (Filtered)

[moneytree1] 20/3/2018 11:18

I bet you had a little peak pappy

[papillon] 20/3/2018 11:03

moneytree1 20 Mar '18 - 10:37 - 2540 of 2541 (Filtered)

0 0 0
moneytree1 20 Mar '18 - 10:39 - 2541 of 2541 (Filtered)

[moneytree1] 20/3/2018 10:37

small time big mouth paps.

LOL

[papillon] 20/3/2018 10:35

I am chilled, bazworth. I only have 20k shares @ circa 20p average. All paid for. I have no open positions. I don't spread bet. It can go sub 17p, in the short term, for all I care, though I'd prefer it not to.

Unlike diamondstar I have no knowledge of the biopharma industry, but then I used to dabble in oil shares and I have no oil industry knowledge either. I'm just a small time gambler and like most small time gamblers, with no expert knowledge, I get it wrong more times than I get it right, like the vast majority of small time stock market gamblers.

All I know is that the AMYT chart went poosibly bearish after it couldn't break above the circa 27p closing price resistance last summer and it went bearish after it broke through support @ 20.30p following the placing news of 21st September, which turned into resistance. It failed to break through that 20.30p resistance earlier this month. I had hoped that the update of last Thursday would be considered good enough by the market for a break above that rsistance. The market wasn't that impressed so the share price is where it is! Nothing I can do to change that sp, bazworth. As a small shareholder I can't influence the direction of the share price All I can do is sell, buy, or hold. For better, or worse, I've decided to hold. A gut decision and not based on any biopharma knowledge. I'm just a bog standard, know nothing, outsider having a punt. At this moment in time my punt has gone wrong. C'est la vie!

[diamondstar1] 20/3/2018 09:38

Yes, there is some truth in what you have said paps. There are new data transparency laws supported by the FDA and EMA requiring pharma companies to share the data from their clinical trails, irrespective of whether the study is a failure or positive.
So, Amryt could have made a formal request to Amicus for the data, in accordance with data transparency.
But in this case, my personal feeling is that the data sharing could have gone beyond a simple data transaction - that Amryt used this opportunity to build bridges with Amicus. Only Amryt/Amicus Senior Management will know the truth!

[papillon] 19/3/2018 23:00

I saw this posted on the lse bb. Make of it what you will. I've never been on this tradingview site before. It's news that drives share prices and the Market didn't think too much of Thursday's news, as evidenced in the direction of the share price since Thursday.



IMO the AMYT share price closed just above support today. Will that support hold? I don't know. It wouldn't be a positive sign if that support failed IMO.

What today's bullish posters on the lse bb forget is that it matters not one jot if they think AMYT is currently undervalued; it's what the Market as a whole thinks of the company and if the Market is currently bearish you just have to accept it.

[papillon] 19/3/2018 22:22

It's ppossible (probable?) that AMICUS shared the futile Zorbilsa phase III trial data with other companies, apart from AMYT. Sounds like AMICUS made available the data to others and that AMYT were not given special status by AMICUS.

"Crowley said the data from the trial will be shared"

[diamondstar1] 19/3/2018 14:44

These are all very good points raised. My personal read on the situation... if you conduct a study and the primary endpoint is achieved in patients with Dystrophic EB (DEB) and Junctional EB (JEB), then Regulators (Eg FDA, EMEA) will consider granting approval of the drug in the target population (DEB/JEB). This will usually be reflected in the drug label. However, I believe that Amryt can put a case to Regulators to try to use the data they have already generated in EB Simplex patients. Perhaps a sub analysis of data in the EBS patients who were already enrolled in this study might support this, for example, if mean healing rates were 30% faster in the episalvan vs placebo arm in EBS patients. However, it is not an automatic assumption that the drug will be effective in the milder EBS form, because it is effective in DEB/JEB.

With regards to the previous planned interims - I personally don’t think they have analysed the data. The adaptation to the study design, in theory, should be before the data was examined. Otherwise, adaptation of the study after examining the interim data, can clearly bias the outcome and results of the study.

[digadee] 19/3/2018 14:04

I read it the same as spuddy. I dont beleive simplex is out the window for EB treatment, surely if it can help severe cases then it can help the minor EB symptom too

[spuddymadrid] 19/3/2018 13:47

I dont think the adjustment is the phase 111 trials to not include simplex patients in tests means that simplex patients will not covered by Episalvin should Amryt get go ahead. I read things differently. It just appears that the improvemnts in patients with more severe EB subset types are easier to judge but no where do we see stated that upon a successful phase 111 conclusion EB will not be approved for the Simplex subset. Think this needs clarification !!!

[moneytree1] 18/3/2018 19:44

who gives a toss paps.

[papillon] 18/3/2018 19:38

digadee 18 Mar '18 - 14:10 - 2525 of 2527
0 0 0
Hi paps

U were in this for EB as you have kept on saying and if you feel how u feel about the outcome (your last post) then best you sell up?

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

I'VE ALWAYS SAID I WOULD STAY INVESTED IN AMYT UNTIL THE INTERIM RESULTS ARE ISSUED, digadee, FOR GOOD, OR BAD, SO I WILL. THAT MEANS I'M HERE UNTIL EARLY Q4 2018